Duopharma Biotech Bhd (7148)
Kuala Lumpur Exchange · Malaysia · prices in MYR · close of 19 Oct 2026
Key indicators
| Last close | MYR 1.090 |
|---|---|
| 52-week range | 1.060 – 1.519 |
| Return, 1 month / 3 months | −6.8% / −9.6% |
| Return, 1 year / 3 years | −13.4% / +0.5% |
| Trend | Below its 200-day average |
| RSI (14) | 35 |
| Volatility (1 year) | 26.7% |
| Worst drawdown (1 year) | -28.0% |
| Average daily value traded | 0.47M MYR |
| Dividend yield | 4.2% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Duopharma Biotech is a Malaysian pharmaceutical company that develops, manufactures and markets prescription medicines, generic drugs and over-the-counter healthcare products. Its range covers therapeutic areas such as cardiovascular, respiratory and anti-infective treatments, along with consumer health items including supplements and personal care products. The company serves hospitals, clinics, pharmacies and healthcare distributors, mainly in Malaysia, and also produces halal-certified medicines for Muslim patients. It is based in Malaysia and is part of a larger pharmaceutical group.
The shares are listed on the Kuala Lumpur Exchange in Malaysia under the code 7148, and the price on this page is in Malaysian ringgit (MYR). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Duopharma Biotech Bhd (7148) trades on the Kuala Lumpur Exchange in Malaysia. It last closed at MYR 1.090 on 19 October 2026.
Its price-based Market X-Ray is 50 out of 100 (a fair price profile), ranking 549 of 1,066 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 13.4% and over the last three months it fell 9.6%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Kuala Lumpur Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 33 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -13.1% | ||
| From 52-week high | -27.3% | ||
| Momentum | 36 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -9.6% | ||
| 6-month return | -14.5% | ||
| 12-month return, skipping the last month | -7.0% | ||
| Stability (higher is calmer) | 68 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 26.7% | ||
| Worst drawdown, 1 year (smaller is calmer) | -28.0% | ||
| Liquidity | 70 · Fair | Moderate trading activity. | |
| Average daily value traded | 0.47M MYR | ||
| Zero-volume days | 1.7% | ||
| Income | 57 · Fair | Dividend is typical for this exchange. | |
| Dividend yield | 4.2% | ||
| Years with dividends | 5 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
Returns
| 1 week | −1.8% |
|---|---|
| 1 month | −6.8% |
| 3 months | −9.6% |
| 6 months | −14.5% |
| 1 year | −13.4% |
| 3 years | +0.5% |
| 5 years | – |
Signals
| 50-day / 200-day average | 1.192 / 1.255 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.029 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 3 Sep 2026 | MYR 0.0150 |
| 12 Mar 2026 | MYR 0.0305 |
| 8 Sep 2025 | MYR 0.0150 |
| 5 Mar 2025 | MYR 0.0200 |
| 29 Aug 2024 | MYR 0.0100 |
| 7 Mar 2024 | MYR 0.0180 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Kuala Lumpur Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.